Backstrom Jay T. 4

What Happened

• Jay T. Backstrom, a director of Agios Pharmaceuticals (AGIO), was credited with 1,447 restricted stock units (RSUs) on July 8, 2026 (reported as an acquisition at $0.00). The Form 4 also shows a corresponding exercise/conversion of a derivative for 1,447 shares at $0.00. No cash changed hands per the filing — the transactions are reported at $0.00.

Key Details

• Transaction date: July 8, 2026 (reported on Form 4 filed July 10, 2026).
• Reported price: $0.00 for both the RSU grant (A) and the derivative exercise/conversion (M).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 — each RSU represents a contingent right to one share; F2 — RSUs were originally granted July 8, 2025 and will begin vesting July 8, 2026 in three equal annual installments.
• Filing timeliness: Filed July 10, 2026 for a July 8 transaction — appears timely (Form 4 is due within two business days).

Context

• This is an equity award (compensation/grant), not an open-market purchase or sale; awards are often routine director compensation and don’t by themselves signal a buy/sell decision.
• The derivative line likely reflects conversion/exercise treatment of a prior derivative instrument into the RSU/share reporting — both entries are at $0.00, which reflects the grant/exercise price reported, not the market value of the shares.
• Vesting is delayed: the shares underlying these RSUs begin vesting July 8, 2026 and will vest in three equal annual installments per the footnote.